Cardiol Therapeutics Inc.
CRDLNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Regular session
$1.775
−$0.085 · -4.57%
CRDL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
28
Expensive
Momentum
30
Weakening
Sentiment
43
Mixed
Risk resilience
49
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- David G. Elsley
- Listed since
- Jan 15, 2019
- Employees
- 18
Market position
Day range
Current $1.775
52-week range
Current $1.775
- Open
- $1.88
- Previous close
- $1.86
- Volume
- 317.12K
- 0.44× average
- Average volume
- 719.26K
- Average daily volume
- Market cap
- 204.61M USD
- Beta
- 0.47
- Market reference 1
- 50-day average
- $1.2584
- +41.05% above average
- 200-day average
- $1.1546
- +53.73% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 92.56M CAD
- P/E (TTM)
- -7.15×
- P/B (TTM)
- 11.77×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.75×
- Earnings yield
- -29.71%
- Free cash flow yield
- -20.97%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -189.17%
- Return on assets
- -143.18%
- Return on invested capital
- -190.61%
Financial health
- Debt / equity
- 0×
- Current ratio
- 4.16×
- Altman Z-score
- 19.27
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (CAD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 62.27K CAD |
| Cost of goods sold | — | — | 187.38K CAD | 162.23K CAD | 174.26K CAD |
| Gross profit | — | — | −187.38K CAD | −162.23K CAD | −112K CAD |
| Research and development | 14.02M CAD | 14.01M CAD | 10.73M CAD | 13.99M CAD | 8.59M CAD |
| Selling, general, and administrative | 20.2M CAD | 25.89M CAD | 11.55M CAD | 16.34M CAD | 21.86M CAD |
| Operating expenses | 34.32M CAD | 40.28M CAD | 22.29M CAD | 30.33M CAD | 30.46M CAD |
| Interest income | 726.4K CAD | 1.19M CAD | 2.04M CAD | 1.24M CAD | 106K CAD |
| Depreciation and amortization | 101.98K CAD | 162.11K CAD | 187.38K CAD | 162.23K CAD | 174.26K CAD |
| Operating income | −34.32M CAD | −40.28M CAD | −22.47M CAD | −30.49M CAD | −30.57M CAD |
| Net income | −33.82M CAD | −36.68M CAD | −21.22M CAD | −22.82M CAD | −25.01M CAD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 2 misses, 2 met estimates
- Average EPS surprise
- +9.45%
- 11 comparable reports
- Latest EPS result
- -0.04
- Estimate -0.09 · Beat by 55.56%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$8.00
350.70% upsideRecent analyst actions
CRDL news
CRDL peers
Continue in GoAI
Research CRDLresearch.disclaimer